1. Epigenetics
    Cell Cycle/DNA Damage
    Autophagy
  2. HDAC
    Autophagy

Belinostat (Synonyms: PXD101; PX105684)

Cat. No.: HY-10225 Purity: 99.66%
Data Sheet SDS Handling Instructions

Belinostat is a potent HDAC inhibitor with an IC50 of 27 nM in HeLa cell extracts.

For research use only. We do not sell to patients.
Belinostat Chemical Structure

Belinostat Chemical Structure

CAS No. : 866323-14-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $72 In-stock
10 mg $65 In-stock
50 mg $150 In-stock
100 mg $220 In-stock
200 mg $350 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Belinostat is a potent HDAC inhibitor with an IC50 of 27 nM in HeLa cell extracts.

IC50 & Target

IC50: 27 nM (HDAC, in HeLa cells)[1]

In Vitro

Belinostat (PXD101) induces a concentration-dependent (0.2-5 μM) increase in acetylation of histone H4 in tumor cell lines. Belinostat is cytotoxic in vitro in a number of tumor cell lines with IC50s in the range 0.2-3.4 μM as determined by a clonogenic assay and induces apoptosis. Belinostat inhibits the growth of a number of human tumor cell lines in vitro with IC50s determined by a clonogenic assay in the range 0.2-3.4 μM[1]. Belinostat (PXD101) is a potent histone deacetylase (HDAC) inhibitor, potently inhibits the enzymatic activity of purified recombinant HDAC6 (IC50 of 82 nM)[2].

In Vivo

Treatment of nude mice bearing human ovarian and colon tumor xenografts with Belinostat (10-40 mg/kg/day i.p.) daily for 7 days causes a significant dose-dependent growth delay with no obvious signs of toxicity to the mice. Growth delay is also observed for xenografts of cisplatin-resistant ovarian tumor cells. A marked increase in acetylation of H4 is detected in blood and tumor of mice 3 h after treatment with Belinostat (PXD101). The inhibition of growth of human tumor xenografts in mice, with no apparent toxicity[1]. Belinostat (PXD101) displays single-agent antitumor activity on human A2780 ovarian cancer s.c. xenografts which is enhanced via combination therapy with Carboplatin[2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01317927 Spectrum Pharmaceuticals, Inc|Onxeo Solid Tumor|Hematological Malignancy December 2010 Phase 1
NCT02679131 Spectrum Pharmaceuticals, Inc Relapsed/Refractory Solid Tumors/Hematological Malignancies March 2016 Phase 1
NCT01583777 Spectrum Pharmaceuticals, Inc Advanced Cancer September 2013 Phase 1
NCT00413075 Onxeo|Spectrum Pharmaceuticals, Inc Solid Tumor|Lymphoma June 2006 Phase 1
NCT02142530 Massachusetts General Hospital|National Comprehensive Cancer Network Non-Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Peripheral T-cell Lymphoma October 2014 Phase 1
NCT00274651 Onxeo Cutaneous T-Cell Lymphoma|Peripheral T-Cell Lymphoma|Non-Hodgkin's Lymphoma January 2006 Phase 2
NCT01090830 Holy Cross Hospital, Florida Non-Small-Cell Lung Carcinoma April 2010 Phase 1|Phase 2
NCT00321594 National Cancer Institute (NCI) Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer May 2006 Phase 1|Phase 2
NCT00421889 Onxeo Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Bladder Cancer August 2005 Phase 1|Phase 2
NCT02381548 National Cancer Institute (NCI) Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia August 18, 2015 Phase 1
NCT01839097 Spectrum Pharmaceuticals, Inc Peripheral T-cell Lymphoma May 2013 Phase 1
NCT00301756 National Cancer Institute (NCI) Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor|Recurrent Ovarian Carcinoma|Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor|Stage III Ovarian Cancer|Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor|Stage IV Ovarian Cancer September 2006 Phase 2
NCT00357162 National Cancer Institute (NCI) de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Secondary Myelodysplastic Syndromes May 2006 Phase 2
NCT02680795 Spectrum Pharmaceuticals, Inc Solid Tumors|Hematological Malignancies March 2016 Phase 1
NCT00334789 National Cancer Institute (NCI) Adult Solid Neoplasm June 12, 2006 Phase 1
NCT02137759 Emory University|Johns Hopkins University|Spectrum Pharmaceuticals, Inc|National Cancer Institute (NCI) Glioblastoma Multiforme of Brain May 2014 Phase 2
NCT01188707 Herlev Hospital|Copenhagen University Hospital at Herlev|Bispebjerg Hospital|Onxeo|Roche Pharma AG Non Small Cell Lung Cancer December 2010 Phase 1|Phase 2
NCT01273155 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms|Lymphomas December 22, 2010 Phase 1
NCT01310244 Spectrum Pharmaceuticals, Inc|Onxeo Stage IV Non-small Cell Lung Cancer December 2010 Phase 1|Phase 2
NCT01686165 University of Arizona|National Cancer Institute (NCI) Anaplastic Large Cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma August 31, 2012 Phase 2
NCT00413322 Onxeo Tumor September 2005 Phase 1
NCT01075425 Virginia Commonwealth University|National Cancer Institute (NCI) Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia May 2010 Phase 1
NCT00357032 National Cancer Institute (NCI) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia May 2006 Phase 2
NCT00993616 National Cancer Institute (NCI) Brenner Tumor|Fallopian Tube Cancer|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer December 2009 Phase 2
NCT00365053 National Cancer Institute (NCI) Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma June 2006 Phase 2
NCT02737046 University of Miami Adult T-cell Leukemia-Lymphoma|ATLL December 12, 2016 Phase 2
NCT00351975 National Cancer Institute (NCI) Accelerated Phase of Disease|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemi June 2006 Phase 1
NCT00873119 Onxeo|Spectrum Pharmaceuticals, Inc Carcinoma of Unknown Primary February 2009 Phase 2
NCT00589290 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Thymoma|Thymic Carcinoma December 2007 Phase 2
NCT02701673 M.D. Anderson Cancer Center Lymphoma June 2016 Phase 1|Phase 2
NCT02875002 Yale University|Massey Cancer Center|Sidney Kimmel Comprehensive Cancer Center Relapsed and Refractory Aggressive B- and T-cell Lymphomas|Lymphoma October 2016 Phase 1
NCT00303953 National Cancer Institute (NCI) Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma January 2006 Phase 2
NCT00348985 National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cel March 2006 Phase 1
NCT02532192 M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc Lymphoma December 2015 Phase 1
NCT00926640 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Carcinoma Neuroendocrine|Small Cell Lung Carcinoma|Malignant Epithelial Neoplasms June 17, 2009 Phase 1
NCT00354185 National Cancer Institute (NCI) Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphoma May 2006 Phase 1
NCT01317927 Spectrum Pharmaceuticals, Inc|Onxeo Solid Tumor|Hematological Malignancy December 2010 Phase 1
NCT02679131 Spectrum Pharmaceuticals, Inc Relapsed/Refractory Solid Tumors/Hematological Malignancies March 2016 Phase 1
NCT01583777 Spectrum Pharmaceuticals, Inc Advanced Cancer September 2013 Phase 1
NCT00413075 Onxeo|Spectrum Pharmaceuticals, Inc Solid Tumor|Lymphoma June 2006 Phase 1
NCT02142530 Massachusetts General Hospital|National Comprehensive Cancer Network Non-Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Peripheral T-cell Lymphoma October 2014 Phase 1
NCT00274651 Onxeo Cutaneous T-Cell Lymphoma|Peripheral T-Cell Lymphoma|Non-Hodgkin's Lymphoma January 2006 Phase 2
NCT01090830 Holy Cross Hospital, Florida Non-Small-Cell Lung Carcinoma April 2010 Phase 1|Phase 2
NCT00321594 National Cancer Institute (NCI) Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer May 2006 Phase 1|Phase 2
NCT00421889 Onxeo Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Bladder Cancer August 2005 Phase 1|Phase 2
NCT02381548 National Cancer Institute (NCI) Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia August 18, 2015 Phase 1
NCT01839097 Spectrum Pharmaceuticals, Inc Peripheral T-cell Lymphoma May 2013 Phase 1
NCT00301756 National Cancer Institute (NCI) Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor|Recurrent Ovarian Carcinoma|Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor|Stage III Ovarian Cancer|Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor|Stage IV Ovarian Cancer September 2006 Phase 2
NCT00357162 National Cancer Institute (NCI) de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Secondary Myelodysplastic Syndromes May 2006 Phase 2
NCT02680795 Spectrum Pharmaceuticals, Inc Solid Tumors|Hematological Malignancies March 2016 Phase 1
NCT00334789 National Cancer Institute (NCI) Adult Solid Neoplasm June 12, 2006 Phase 1
NCT02137759 Emory University|Johns Hopkins University|Spectrum Pharmaceuticals, Inc|National Cancer Institute (NCI) Glioblastoma Multiforme of Brain May 2014 Phase 2
NCT01188707 Herlev Hospital|Copenhagen University Hospital at Herlev|Bispebjerg Hospital|Onxeo|Roche Pharma AG Non Small Cell Lung Cancer December 2010 Phase 1|Phase 2
NCT01273155 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms|Lymphomas December 22, 2010 Phase 1
NCT01310244 Spectrum Pharmaceuticals, Inc|Onxeo Stage IV Non-small Cell Lung Cancer December 2010 Phase 1|Phase 2
NCT01686165 University of Arizona|National Cancer Institute (NCI) Anaplastic Large Cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma August 31, 2012 Phase 2
NCT00413322 Onxeo Tumor September 2005 Phase 1
NCT01075425 Virginia Commonwealth University|National Cancer Institute (NCI) Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia May 2010 Phase 1
NCT00357032 National Cancer Institute (NCI) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia May 2006 Phase 2
NCT00993616 National Cancer Institute (NCI) Brenner Tumor|Fallopian Tube Cancer|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer December 2009 Phase 2
NCT00365053 National Cancer Institute (NCI) Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma June 2006 Phase 2
NCT02737046 University of Miami Adult T-cell Leukemia-Lymphoma|ATLL December 12, 2016 Phase 2
NCT00351975 National Cancer Institute (NCI) Accelerated Phase of Disease|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemi June 2006 Phase 1
NCT00873119 Onxeo|Spectrum Pharmaceuticals, Inc Carcinoma of Unknown Primary February 2009 Phase 2
NCT00589290 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Thymoma|Thymic Carcinoma December 2007 Phase 2
NCT02701673 M.D. Anderson Cancer Center Lymphoma June 2016 Phase 1|Phase 2
NCT02875002 Yale University|Massey Cancer Center|Sidney Kimmel Comprehensive Cancer Center Relapsed and Refractory Aggressive B- and T-cell Lymphomas|Lymphoma October 2016 Phase 1
NCT00303953 National Cancer Institute (NCI) Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma January 2006 Phase 2
NCT00348985 National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cel March 2006 Phase 1
NCT02532192 M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc Lymphoma December 2015 Phase 1
NCT00926640 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Carcinoma Neuroendocrine|Small Cell Lung Carcinoma|Malignant Epithelial Neoplasms June 17, 2009 Phase 1
NCT00354185 National Cancer Institute (NCI) Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphoma May 2006 Phase 1
NCT00878800 Onxeo|Spectrum Pharmaceuticals, Inc Dose Escalation: Solid Tumors|MTD: Soft Tissue Sarcomas December 2006 Phase 1|Phase 2
NCT00878722 Onxeo Acute Myeloid Leukemia August 2007 Phase 1|Phase 2
NCT00865969 Spectrum Pharmaceuticals, Inc|Onxeo Peripheral T-cell Lymphoma December 2008 Phase 2
NCT01100944 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Thymoma|Thymic Carcinoma March 2010 Phase 1|Phase 2
NCT00131261 Onxeo Multiple Myeloma January 2005 Phase 2
NCT00431340 Onxeo Multiple Myeloma March 2007 Phase 2
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 3.1412 mL 15.7060 mL 31.4120 mL
5 mM 0.6282 mL 3.1412 mL 6.2824 mL
10 mM 0.3141 mL 1.5706 mL 3.1412 mL
Kinase Assay
[1]

For activity assays, the reaction is carried out in a total volume of 150 μL of buffer [60 mM Tris (pH 7.4) containing 30% glycerol] containing 2 μL of cell extract and, where used, 2 μL of Belinostat. The reaction is started by the addition of 2 μL of [3H]labeled substrate (acetylated histone H4 peptide corresponding to the 20 NH2-terminal residues). Samples are incubated at 37°C for 45 min, and the reaction stopped by the addition of HCl and acetic acid (0.72 and 0.12 M final concentrations, respectively). Released [3H]acetate is extracted into 750 μL of ethyl acetate, and samples are centrifuged at 12,000× g for 5 min. The upper phase (600 μL) is transferred to 3 mL of scintillation fluid and counted[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

Belinostat (PXD101) is solubilized in DMSO and stored, and then diluted with appropriate media before use[1].

The human ovarian cell line A2780 and Cisplatin (A2780/cp70) and Doxorubicin (2780AD) resistant derivatives are grown in RPMI 1640 supplemented with glutamine (2 mM) and FCS (10%). The human colon (HCT116 and HT29), melanoma (HS852), prostate (PC3), lung (CALU-3), and breast (MCF7) cell lines are grown in RPMI 1640 and the rest in DMEM supplemented as above. The human non-small cell lung cancer cell line WIL is grown in DMEM supplemented as above. Drug sensitivity is determined by a clonogenic assay. Briefly, cells are plated in 5 mL of medium at a density of 8×104 cells/25 cm2 flask and allowed to attach and grow for 48 h. Cells are exposed to Belinostat (five concentrations from 0.016 to 10 μM) for 24 h. The medium is removed, and 1 mL of trypsin/EDTA is added to each flask. Once the cells have detached, 1 mL of medium is added, the cells are resuspended, and those from the control untreated flask are counted. Cells are diluted and plated into 6-cm Petri dishes (three per flask) at a density of 500-2000 cells/dish depending on the cell line. Cells from the drug-treated flasks are diluted and plated as for the control flasks. Dishes are incubated for 10-15 days at 37°C. Cells are washed with PBS, fixed in methanol, and stained with crystal violet, and colonies that contained ≥50 cells counted. Sensitivity is expressed as the IC50 (mean±SE of three experiments) defined as the concentration of drug required to reduce the number of colonies to 50% of that of the control untreated cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Belinostat (PXD101) is dissolved in DMSO and then diluted in water to give a final concentration of DMSO of 10% (Mice)[1].

Mice[1]
For the human tumor xenograft studies, monolayer cultures are harvested with trypsin/EDTA (0.25%/1 mM in PBS) and resuspended in PBS. About 107 cells are injected s.c. into the right flank of athymic nude mice (CD1 nu/nu mice). After 10-15 days when the mean tumor diameter is ≥0.5 cm, animals are randomized into groups of six for experiments. Belinostat is dissolved in DMSO and then diluted in water to give a final concentration of DMSO of 10% and is administered i.p. at the times specified. This formulation gives sufficient solubility for doses of ≤ 40 mg/kg. Mice are weighed daily, and tumor volumes are estimated by caliper measurements assuming spherical geometry (volume=d3×π/6). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
M.Wt

318.35

Formula

C₁₅H₁₄N₂O₄S

CAS No.

866323-14-0

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.66%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Belinostat
Cat. No.:
HY-10225
Quantity: